Intellia Therapeutics, Inc.(NTLA)NASDAQ
Stock Performance & Returns
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
NTLA | 1.78 B | -3.80x | -46.20% | - | $-3.34 | -55.44% | 0.10 | - | $28.25 | $7.95 |
IMNM | 3.08 B | -10.74x | - | - | $-2.53 | -64.03% | 0.90 | - | $30.06 | $8.66 |
VRDN | 2.60 B | -6.75x | 2.79% | - | $-3.40 | -65.74% | 0.37 | - | $34.29 | $13.18 |
BCRX | 2.58 B | -7.21x | 33.60% | -40.90% | $-1.40 | - | - | - | $11.22 | $6.00 |
RARE | 1.46 B | -2.55x | 28.10% | -81.73% | $-5.83 | - | - | - | $39.89 | $18.29 |
Peer Valuation & Performance Analysis
Peer group analysis for Intellia Therapeutics, Inc. (NTLA) compared to its primary competitors (including IMNM, VRDN, BCRX) reveals distinct metrics. NTLA trades at a valuation premium compared to its competitors, with a P/E ratio of -3.8x versus the peer average of -6.8x (representing a -44% premium). This indicates that the market expects superior growth or commands a quality premium for NTLA. In terms of growth, NTLA's revenue growth of -46.2% lags behind the peer average of 21.5%, indicating potential market share losses or slower industry adoption.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• NTLA ranks #0 in P/E ratio, #5 in revenue growth, and #1 in profit margins
• Average ranking: #2 - 🎯 Top-tier fundamentals relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-09-03 | $12.86 | $12.92 | $12.40 | $12.68 | 3,002,200 | -1.40% |
| 2026-09-02 | $12.67 | $13.13 | $12.28 | $12.76 | 3,244,100 | +0.71% |
| 2026-09-01 | $12.52 | $12.81 | $12.34 | $12.69 | 2,179,700 | +1.32% |
| 2026-08-31 | $12.64 | $12.85 | $12.44 | $12.73 | 2,923,100 | +0.71% |
| 2026-08-28 | $13.11 | $13.49 | $12.68 | $12.87 | 3,437,300 | -1.83% |
| 2026-08-27 | $13.26 | $13.45 | $13.00 | $13.11 | 2,444,900 | -1.13% |
| 2026-08-26 | $13.38 | $13.50 | $12.98 | $13.19 | 2,707,200 | -1.42% |
| 2026-08-25 | $12.84 | $13.73 | $12.76 | $13.51 | 4,089,700 | +5.22% |
| 2026-08-24 | $12.60 | $12.79 | $12.24 | $12.56 | 3,110,500 | -0.32% |
| 2026-08-21 | $12.65 | $13.13 | $12.65 | $12.84 | 3,345,900 | +1.50% |
| 2026-08-20 | $12.95 | $13.04 | $12.29 | $12.44 | 4,703,600 | -3.94% |
| 2026-08-19 | $12.10 | $13.35 | $12.01 | $13.28 | 6,102,300 | +9.75% |
| 2026-08-18 | $11.80 | $12.10 | $11.44 | $11.60 | 3,177,100 | -1.69% |
| 2026-08-17 | $11.91 | $12.22 | $11.75 | $12.09 | 1,818,800 | +1.51% |
| 2026-08-14 | $11.83 | $12.04 | $11.41 | $11.91 | 2,359,200 | +0.68% |
Explore More Analysis for NTLA
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.